•  
  •  
 

Authors

Mara L. Becker, Duke Clinical Research Institute, Durham, NC USA; Duke University School of Medicine, Durham, NC USAFollow
Gwenyth Fischer, University of Minnesota Masonic Children’s Hospital, Minneapolis, MN USA
Chi D. Hornik, Duke Clinical Research Institute, Durham, NC USA; Duke University School of Medicine, Durham, NC USA
Omar Alibrahim, Duke University School of Medicine, Durham, NC USA
Kelechi Iheagwara, Our Lady of the Lake Regional Medical Center, Baton Rouge, LA USA
Kamal Abulebda, Riley Hospital for Children at Indiana University Health, Indianapolis, IN USA
Andora L. Bass, Wake Forest School of Medicine, Winston-Salem, NC USA
Katherine Irby, Arkansas Children’s Hospital, Little Rock, AR USA
Anjali Subbaswamy, University of New Mexico, Albuquerque, NM USA
Elizabeth E. Zivick, MUSC Shawn Jenkins Children’s Hospital, Charleston, SC USA
Jill Sweney, Primary Children’s Medical Center – University of Utah, Salt Lake City, UT USA
Anne G. Stormorken, UH Rainbow Babies and Children's Hospital, Cleveland, OH USA
Erin E. Barker, University of Rochester, Rochester, NY USA
Shruthi Mahadaveiah, University of Florida College of Medicine, Gainesville, FL USA
Riad Lutfi, Riley Hospital for Children at Indiana University Health, Indianapolis, IN USA
Michael C. McCrory, Wake Forest School of Medicine, Winston-Salem, NC USA
John M. Costello, MUSC Shawn Jenkins Children’s Hospital, Charleston, SC USA
Kate G. Ackerman, University of Rochester, Rochester, NY USA
Jennifer C. Munoz-Pareja, University of Florida College of Medicine, Gainesville, FL USA
Bryan J. Feger, Duke Clinical Research Institute, Durham, NC USA
J. Michael Dean, University of Utah, Salt Lake City, UT USA
Daniel F. Hanley, Johns Hopkins University School of Medicine, Baltimore, MD USA
Rachel G. Greenberg, Duke Clinical Research Institute, Durham, NC USA; Duke University School of Medicine, Durham, NC USA
Radhika Avadhani, Johns Hopkins University School of Medicine, Baltimore, MD USA
Richard E. Thompson, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA
Daniel K. Benjamin, Duke Clinical Research Institute, Durham, NC USA; Duke University School of Medicine, Durham, NC USA
Christoph P. Hornik, Duke Clinical Research Institute, Durham, NC USA; Duke University School of Medicine, Durham, NC USA
Kanecia O. Zimmerman, Duke Clinical Research Institute, Durham, NC USA; Duke University School of Medicine, Durham, NC USA

Abstract

Objectives: To observe the mean daily dose of fentanyl required for adequate sedation in critically ill, mechanically ventilated children randomized to receive dexmedetomidine or placebo. Methods: We conducted Dexmedetomidine Opioid Sparing Effect in Mechanically Ventilated Children (DOSE), a multicenter, double-blind, randomized, placebo-controlled, dose-escalating trial. We enrolled children aged 35 weeks post-menstrual to 17 years (inclusive) admitted across 13 pediatric multidisciplinary and cardiac intensive care units. Adequate sedation was based on a State Behavioral Score and Richmond Agitation-Sedation Scale of -1 or lower. Only the first two dexmedetomidine dosing cohorts opened for enrollment, due to early trial closure during the coronavirus 2019 pandemic. Thirty children were randomized over 13 months and included in the analyses. Results: Demographic and baseline characteristics were not different between dexmedetomidine and placebo cohorts. Similarly, mean daily fentanyl use was not different, using an unadjusted mixed regression model that considered treatment, time, and a treatment-by-time interaction. Adverse events and safety events of special interest were not different between cohorts. Conclusions: The DOSE trial revealed that dexmedetomidine added to fentanyl does not impact safety and may not spare fentanyl use in critically ill children, although the trial did not meet its recruitment goals, due to early closure during the coronavirus 2019 pandemic. More rigorous inpatient pediatric trials like DOSE that study critically ill, mechanically ventilated children are needed. Despite the many obstacles faced, the DOSE trial presents challenges from which the greater research community can learn and use to optimize future therapeutic trials in children.

Share

COinS